15 Quotes by Glenn Reicin

The opportunity to expand into other markets could be significant.

We think it is unlikely that these changes will modify purchasing and demand characteristics of medical devices. Hospitals have traditionally had little leverage in reducing device costs.

We think investors will look past third-quarter guidance, as the company has historically been overly conservative, and react favorably to the quarter.

Boston Scientific still has much 'wood to chop' regarding the recovery of the company's cardiac rhythm management business...That said, we believe earnings power for businesses remain substantial.

Greater clarity regarding this transaction and future growth goals (without the Guidant acquisition) are needed,

The device replacements will cause companies to forgo revenue producing replacement units in future years.